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showed a strong trend for less CV-events (p = 0.098). Cost-
effectiveness of screening for elevated albuminuria was.
€16,559/LYG (from €7,030 to €24,125 in sensitivity analysis).
Stochastic analysis indicated that the probability of cost-
effectiveness below the suggested Dutch threshold for cost-
effectiveness of €20,000 per LYG is 60% in the baseline 
analysis, increasing to 91% if only those subjects are treated with
fosinopril showing a UAE >50mg/24hr. Also, limiting screening
to only those aged greater or equal than 50; improved cost-
effectiveness considerably. CONCLUSION: Primary prevention
by screening the general population for the risk marker albu-
minuria greater or equal to 15mg/24hr and subsequent treat-
ment with fosinopril of those found positive to reduce the
incidence of CV events may well be cost effective.
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OBJECTIVES: To evaluate short-term (12 months) cost-
effectiveness (CE) of intravenous (iv) vitamin D preparations
(paricalcitol and calcitriol) to control hyperparathyroidism in
hemodialysis patients. METHODS: A decision analytic model
was constructed and analysed from the hospital and the Italian
National Health System (INHS) perspectives. Following the indi-
cations of the Italian Nephrology Society on the use of iv Vitamin
D analogues, patients were simulated to start a 12-month iv
Vitamin D treatment when parathormone (PTH) plasmatic level
was >700pg/ml. Starting doses were 27mg/week for paricalcitol
and 9mg/week for calcitriol; subsequent maintenance dose was
adjusted assuming decreasing PTH levels over time. Model para-
meters were derived from multiple published sources. Clinical
course of treatment and efﬁcacy in controlling hyperparathy-
roidism were based on a RCT (Sprague SM. Kidney Int 2003);
effect on survival, hospitalisation rate and length-of-stay (LOS)
were based on retrospective studies (Teng M. NEJM 2003;
Dobrez DG. Nephrol Dial Transplant 2004). Cost included drug
costs (hospital prices excluding taxes), cost per hospitalization
(national mean DRG value, 2002), in the INHS perspective, or
cost per day of hospitalization (general medical ward, Lucioni
C. et al. Treat Endocrinol 2003), in the hospital perspective.
RESULTS: Per patient one-year drug acquisition costs were
€3364.74 for paricalcitol and 1883.25 for calcitriol. Calcitriol
patients had an average of 0,846 hospitalizations/year more than
paricalcitol at an incremental cost, in the INHS perspective
(DRG tariffs), of €2868.69. Calcitriol patients had an average 
of 9.17 hospitalization/days more than paricalcitol at an incre-
mental cost, in the hospital perspective (LOS), of €2249.58. Par-
icalcitol strategy resulted dominant in both perspectives.
Robustness of these ﬁndings was demonstrated in multiple sen-
sitivity analyses. CONCLUSIONS: In Italy, paricalcitol greater
acquisition costs are offset by reduction in hospitalizations 
and LOS both from an NHS perspective and from the hospital
perspective.
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OBJECTIVES: To demonstrate cost-effectiveness (ICER) of
Mimpara (MIM), a drug against secondary hyperparathyroidism
(sHPT) in dialysis, compared to standard treatment of care
(SOC). METHODS: A Markov model operates in 1/2 year cycles
and runs over 16 years until the starting cohort reaches 70 years.
Mortality risk per cycle was calculated from a 2-year cohort dial-
ysis database (n = 13,000)1. The model uses speciﬁc distributions
for parathyroid hormone (PTH), Calcium (Ca) x Phosphor (P),
age, vintage and MIM dosages (30–120mg/day) from phase III
trials. Patients withdrawing from MIM were treated with SOC.
Average drug costs were €3109/year ﬁrst cycle and €2617/year
subsequent cycles as only drug responders (85%) remained on
study drug. Other treatment costs were taken from a retrospec-
tive cost study in Belgium2 using average daily cost of €214 per
dialysis patient plus €50/day for sHPT-sufferer. Annual 3% dis-
count rate was applied to cost and outcome data. RESULTS:
Running the model in Monte-Carlo simulation (10,000 itera-
tions) over 16 years, delivered a mortality difference of 0.17
years favoring MIM-use for an extra cost of €8027 (+ dialysis
cost) resulting in an ICER of €47,218 per Life Year Gained.
Excluding dialysis costs the ICER was €36,970. Sensitivity analy-
ses ranging discount rates from 0% to 6% independently for
both outcome and cost data showed ICERs of €36,970 and
€59,459 for outcome and €64,517 and €35,088 for cost results,
respectively. Evaluating the ICERs over time indicates that cost-
savings may appear early in MIM-treatment (ﬁrst 2 to 3 years)
due to reductions in co-morbidities without observable survival
beneﬁt. CONCLUSION: Including dialysis costs in the ICER-
equation maintained a reasonable CE-result (<€50,000/LYG)
favoring the use of Mimpara for sHPT.
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OBJECTIVES: Kidney transplantation (KT) is generally
acknowledged as the most clinically effective and cost-effective
option in managing ESRD patients. The objective of our study
was to identify costs and estimate cost-effectiveness of various
ESRD treatment modalities in Latvia. METHODS: We retro-
spectively analysed ﬁles of 250 patients in an in-center hemodial-
ysis treatment mode (HD), 60 patients in continuous ambulatory
peritoneal dialysis treatment mode (CAPD) and 51 patients after
successful KT for the ﬁrst 3 years of treatment. All direct medical
costs were registered. Cost-effectiveness was estimated by costs
per 3 life-years gained. RESULTS: Mean direct costs (in 2003 €)
for one patient for the ﬁrst year and all three years of treatment
were: for CAPD 16,250.0 + €1,577.4 and 48,327.7 ± 1, €162.2
respectively, for HD 14,131.7 ± €1,212.4 and 42,052.4 ±
€1,203.2 respectively, and for KT 15,880.0 ± €4,744.7 and
25,460.0 ± €2,994.4 respectively. Average treatment costs per
patient over the 3 years were the highest in the CAPD group (P
< 0.05 vs. HD, P < 0.001 vs. KT) and KT was the least expen-
sive (as expected). The initial higher costs of KT were fully
recouped within 15 months after surgery. Probability of life
expectancy for CAPD, HD and KT for the ﬁrst and third year
were: 77.3%, 84.1% and 91.3% respectively, and 45.0%, 43.l%
and 83.7% (P < 0.001 vs. CAPD and HD), respectively. The cost
of 3 life-years gained by KT was signiﬁcantly less (P < 0.001)
than the cost associated with CAPD and HD (€29,598.5 vs.
€106,661.1 and €97,798.5 respectively). CONCLUSIONS:
Compared to CAPD and HD, KT provided greater survival ben-
